DGX — Quest Diagnostics Incorporated

Sentiment is constructive but not euphoric as of 2026-09-13. The Q2 2026 print (July 23) was genuinely strong - revenue of $3.04B, +10.2% YoY with 10.0% organic growth, adjusted EPS of $3.12 versus roughly $2.82 consensus, and a raised full-year guide of $11.95-12.05B revenue / $11.05-11.25 adjusted EPS. That prompted target hikes from JPMorgan ($250), Baird ($255), Mizuho ($260) and UBS ($245), lifting the average 12-month target to ~$246.67 and the September Apple Health direct-to-consumer lab panel partnership added a fresh narrative. But the tape disagrees with the targets: DGX is -1.16% over one month and -0.89% over one week, sits 4.9% below its 52-week high of $247.19, and the underlying analyst rating distribution in the data is 13 Buy / 18 Hold / 3 Sell - a consensus 'Hold' with a target implying only ~5% upside. That combination of improving fundamentals and a fully-reflected price is exactly why sentiment reads Neutral rather than Bullish.

The trend is 're-accelerating off a soft patch,' not decaying. Quarterly revenue has climbed from $2.288B (Q4 2023) to $3.043B (Q2 2026), but the YoY cadence is what matters: +8.4% (Q3'24), +14.6% (Q4'24), +12.1% (Q1'25), +15.2% (Q2'25), +13.2% (Q3'25), then a visible air pocket at +7.1% (Q4'25), followed by +9.2% (Q1'26) and +10.2% (Q2'26). So growth decelerated into late 2025 and has since re-accelerated back to roughly 10% - and management explicitly called Q2's growth 10.0% organic, which is well above Quest's historical 2-4% run rate. Caveat: long-term debt jumped from $3.82B (Q2 2024) to $5.65B (Q3 2024) and $6.19B (Q2 2026), with total assets stepping from $13.9B to $16.1B - so a meaningful slice of the multi-year growth was debt-funded M&A, and not all of it is organic. Margins are stable-to-firmer: operating margin has held in a 13.0%-15.9% band for three years (14.1% TTM), with Q2 2026 at 15.1% versus 15.9% in Q2 2025 but gross margin back to 33.7% from 32.5% in Q1 2026. Diluted EPS is the cleanest line: $1.72 (Q1'24) to $2.84 (Q2 2026), with the last two quarters up ~15% YoY ($2.24 vs $1.94; $2.84 vs $2.47). Free cash flow is the one genuinely flat item - TTM FCF of $1.22B (Q3'25-Q2'26) is essentially unchanged from $1.22B a year earlier, and Q1 2026 FCF was soft at $164M before recovering to $330M in Q2. Net: revenue and EPS inflecting upward, margins roughly flat at a decent level, cash generation treading water.

Expensive relative to its own history, and that is the single most important fact in this report. As of 2026-09-13, at $235.02, DGX carries a trailing P/E of 24.6x versus a five-year average of 17.44x, and a P/S of 2.24x versus a five-year average of 1.79x - the deterministic valuation overlay scores this a 9.2/100, labeled 'Rich vs. its own history.' On forward numbers the gap narrows but does not vanish: against FY2026 adjusted EPS guidance of $11.05-11.25 (the dataset's next-FY consensus estimate of $11.192 lines up almost exactly with that range), the forward P/E is ~21.0x. PEG on trailing numbers is 1.95, and EV/EBITDA is 15.98x against a TTM EBITDA of roughly $1.97B. There is a defensible case for a premium multiple - beta of 0.549, a duopoly structure, non-discretionary volume, and a growth rate that has roughly tripled versus history - but 21x forward for a business earning an 8.4% ROIC on a capital-heavy lab network, with leverage that has risen (D/E 0.849), is a full price. The re-rating, not the earnings, has done a lot of the work: the stock is +15.7% over three months and +17.7% over six.

The stock is currently pricing in the beat-and-raise continuing - 21x forward on guidance that already assumes ~15% adjusted EPS growth for 2026 leaves little room for a miss. Read it this way: if organic growth holds at ~10% and the advanced-diagnostics mix (Haystack MRD in New York, AD-Detect pTau217) plus consumer channels keep lifting revenue, the multiple can hold and the shares grind toward the $246.67 consensus target. If organic growth mean-reverts toward the mid-single digits - the historical norm - the multiple likely compresses toward the 17-18x historical range, which on $11.19 of FY2026 EPS implies $190-201, i.e. 15-20% downside even with no earnings cut. The asymmetry is unfavorable at $235 because you are paying peak-multiple for a company whose GAAP-to-adjusted gap is also non-trivial (Q2 2026 GAAP EPS $2.84 versus adjusted $3.12, a ~9% adjustment load). Note the honest tell in the data: a 34-analyst distribution of 13 Buy / 18 Hold / 3 Sell with a $246.67 average target means the street thinks the earnings are real but the price already captures them.

Constructive but no longer cheap on the chart. As of 2026-09-13, RSI(14) sat at 48.76 - dead neutral, neither overbought nor oversold - with price 1.78% below the 20-day SMA and 2.51% above the 50-day, while sitting 16.34% above the 200-day SMA. That is textbook 'uptrend, shallow consolidation': the 3-month (+15.74%) and 6-month (+17.69%) returns confirm the primary trend, while the 1-month (-1.16%) and 1-week (-0.89%) returns show momentum has cooled near the top of the 52-week range ($171.18-$247.19). Entry-timing implication: there is no urgency and no capitulation. The nearest meaningful support is the 50-day (~$229) and then a much deeper gap down to the 200-day area around $202. Scaling in on a pullback toward $220-225, or waiting for the late-October Q3 print to confirm the guidance, is a better risk-adjusted entry than chasing at $235 with RSI mid-range.

• Healthcare utilization and demographic demand: aging US population, expanding preventive/wellness screening, and rising clinical adoption of advanced biomarkers (oncology MRD, Alzheimer's pTau217) provide a structural volume tailwind that is largely insensitive to the economic cycle.
• Reimbursement and regulatory pressure: Medicare Clinical Lab Fee Schedule (PAMA-style) rate cuts and commercial payer pricing pressure remain the single biggest structural risk to revenue per test, and the pending Q3 2026 print will be scrutinized for any pricing softness beneath the volume strength.
• Hospital and health-system cost stress: persistent lab labor and operating pressure at regional hospital networks continues to push reference testing toward Quest's Co-Lab Solutions and lab-management JVs (e.g., Corewell Health), an outsourcing tailwind that expands volume without proportional capital spend.
• Interest rates and leverage: $6.19B of long-term debt against $626M of cash (D/E 0.849) makes refinancing costs and the rate path material; the debt-funded M&A that lifted total assets from $13.9B to $16.1B since mid-2024 means the balance sheet now amplifies rate sensitivity.
• Defensive rotation and low beta: beta of 0.549 makes DGX a natural destination in risk-off healthcare rotations, which is part of why the multiple expanded - but it also means the stock can lag badly in a broad risk-on melt-up, and it offers no cyclical earnings torque.
• Consumerization of testing: the September 2026 Apple Health integration and platforms like questhealth.com open a direct-to-consumer channel with higher-margin, cash-pay economics, but at an unproven scale and with no payor-coverage certainty.

• Q3 2026 earnings in late October 2026 - the central event. Having guided to $11.95-12.05B revenue and $11.05-11.25 adjusted EPS, Quest needs to confirm ~10% organic volume growth and stable margins; a second consecutive beat-and-raise extends the re-rating, while a deceleration is the fastest route to multiple compression from 21x toward the 17-18x historical band.
• Commercial rollout of the Apple Health direct-to-consumer lab-ordering integration later in 2026 - the first real read on whether consumer-initiated testing can move the needle at Quest's scale.
• Advanced diagnostics scaling and payor coverage: NY State approval of the Haystack MRD oncology test and FDA-cleared Roche pTau217 Alzheimer's testing under the AD-Detect portfolio are higher-ASP, higher-margin lines whose reimbursement wins would be genuinely accretive to mix.
• Capital return cadence: the $0.86 quarterly dividend (ex-dividend October 6, 2026, payable October 21) sustains a 1.6% yield, and with $1.22B of TTM FCF against a ~31% payout there is room for further dividend increases or buybacks.
• Additional hospital/lab JV announcements or bolt-on M&A - management has demonstrated appetite (the H2 2024 debt-funded deal), and each deal adds inorganic revenue but also adds leverage.

• Multiple compression risk is the dominant risk. At 21x forward versus a 17.4x five-year average, a return to a normal multiple alone implies roughly $190-201 per share (~15-20% downside) even if earnings estimates hold - and the analyst consensus of 18 Holds out of 34 suggests the street already recognizes this.
• Organic growth durability. A 10.0% organic rate is roughly triple Quest's historical run rate, and part of the multi-year revenue ramp came with long-term debt rising from $3.82B (Q2 2024) to $6.19B (Q2 2026). If utilization normalizes or reimbursement offsets volume, the growth premium in the multiple is unjustified.
• Reimbursement and regulatory risk from Medicare CLFS rate cuts and commercial payer policy changes, which hit revenue per requisition directly and are outside management's control.
• Thin margin buffer: operating margin of ~14% and gross margin of ~33% mean labor wage inflation, PSC operating costs, or supply-chain cost shocks at Quest's thousands of patient service centers flow quickly to EPS; Q2 2026 gross margin of 33.7% was actually down from 34.2% a year earlier.
• Earnings-quality and integration risk from acquisitions - GAAP diluted EPS of $2.84 versus $3.12 adjusted in Q2 2026 means ~9% of reported profitability is non-GAAP adjustments, and the intangible-heavy balance sheet from deals carries future amortization and impairment risk.
• Flat free cash flow: TTM FCF of $1.22B is essentially unchanged YoY despite 10% revenue growth, so the earnings growth is not yet converting into accelerating cash generation.

Quest is a genuinely good, defensive business with a duopoly position, non-discretionary demand, mid-teens adjusted EPS growth, and a strong recent quarter - but at $235.02 on 2026-09-13 you are paying 21x forward earnings for a company whose five-year average P/E is 17.4x and whose TTM free cash flow is flat year over year. This is a case where the fundamentals are better than the deterministic score's 'Fair' label implies, yet the price is worse than the fundamentals justify, and the 13 Buy / 18 Hold / 3 Sell analyst split with a $246.67 target says the same thing: the earnings are real, they are already in the price. I would not be a buyer at current levels; I would be a buyer on a pullback toward the low $200s (near the 200-day SMA and a high-teens forward multiple) or after a Q3 beat-and-raise in late October that proves the 10% organic rate is durable. This is analysis, not personalized financial advice.

Two independent methods converge on ~$224, so I used that as my single figure. (1) Forward P/E: I justified a ~20x multiple - a premium to the 17.44x five-year average for the re-accelerated ~10% organic growth, low beta of 0.549 and defensive volume profile, but a discount to the current 21.0x because ROIC is only 8.4% and a chunk of growth was debt-funded - applied to the FY2026 adjusted EPS estimate of $11.19 (which matches management's $11.05-11.25 guidance midpoint), giving $223.80. (2) EV/EBITDA: 14.5x applied to my 2026E EBITDA of ~$2.09B (on $12.0B revenue at ~14.5% operating margin plus ~$350M D&A) gives $30.3B enterprise value; subtracting net debt of ~$5.57B ($6.19B long-term debt less $626M cash) leaves $24.7B of equity, or $224 per share on ~110.4M shares. Both sit ~5% below the 2026-09-13 price of $235.02 and ~9% below the $246.67 analyst consensus target, consistent with a Neutral lean on a fully valued, good-quality defensive compounder.